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Abstract
Background: We previously analyzed human embryonic kidney (HEK) cell lines for the effects
that simian virus 40 (SV40) small tumor antigen (ST) has on gene expression using Affymetrix U133
GeneChips. To cross-validate and extend our initial findings, we sought to compare the expression
profiles of these cell lines using an alternative microarray platform. METHODS: We have analyzed
matched cell lines with and without expression of SV40 ST using an Applied Biosystems (AB)
microarray platform that uses single 60-mer oligonucleotides and single-color quantitative
chemiluminescence for detection. RESULTS: While we were able to previously identify only 456
genes affected by ST with the Affymetrix platform, we identified 1927 individual genes with the AB
platform. Additional technical replicates increased the number of identified genes to 3478 genes
and confirmed the changes in 278 (61%) of our original set of 456 genes. Among the 3200 genes
newly identified as affected by SV40 ST, we confirmed 20 by QRTPCR including several
components of the Wnt, Notch, and Hedgehog signaling pathways, consistent with SV40 ST
activation of these developmental pathways. While inhibitors of Notch activation had no effect on
cell survival, cyclopamine had a potent killing effect on cells expressing SV40 ST. CONCLUSIONS:
These data show that SV40 ST expression alters cell survival pathways to sensitize cells to the
killing effect of Hedgehog pathway inhibitors.
Background
DNA microarray technology enables the investigator to
quantitate gene expression of hundreds or thousands of
genes from a single RNA sample. However, the various
types of commercially available microarray technologies
have different genomic targets, use different probes design
methodologies, and different detection chemistries mak-
ing cross-platform comparisons difficult. A number of
studies comparing spotted cDNA two-color technology
with the Affymetrix single-color technology have found
fairly poor correlation of data between these two
approaches [1-3]. Other studies comparing oligonucle-
otide platforms such as Agilent and Affymetrix have found
higher correlations [4]. An important difference between
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Affymetrix GeneChips and other oligonucleotide plat-
forms is that Affymetrix uses multiple 25-mer probe pairs,
while all other oligonucleotide microarrays use a single
probe per gene, varying in length from 50 to 70 bases.
A relatively new platform for microarray analysis devel-
oped by Applied Biosystems (AB) employs single 60-mer
oligonucleotides, similar in length to Agilent, but uses sin-
gle-color chemiluminescence detection technology as
opposed to two-color Cy3/Cy5 labeling and laser fluores-
cence scanning. To compare the AB Expression Array Sys-
tem platform with Affymetrix, we analyzed RNA samples
that we had previously analyzed with Affymetrix U133AB
GeneChips [5]. Here we show that the AB platform has
substantially higher sensitivity, detecting four times as
many gene changes in an identical experimental design,
and over seven times as many genes when additional tech-
nical replicates were included. Moreover, the AB microar-
ray data was well correlated with QRTPCR validation data
(R2 = 0.71) while Affymetrix data had lower correlation
with QRTPCR results (R2 = 0.47).
In addition, the genes that were identified solely with the
AB technology provided insights into the mechanisms by
which simian virus 40 small tumor antigen (SV40 ST)
affects transformation of human cells that were not appar-
ent in our earlier analyses. We show that SV40 ST induces
expression of several key components of the Notch, Wnt,
and Hedgehog signaling pathways. While inhibitors of
Notch activation had little effect on cell survival, the
Hedgehog inhibitor cyclopamine had >50% killing effect
on cells expressing SV40 ST, suggesting that SV40 ST
makes cells dependent on Hedgehog signaling for sur-
vival.
Methods
Cell lines
Stable human embryonic (HEK) cell lines HEK-TERST,
HEK-TERV have been described previously [5]. Briefly,
cells were maintained in α-MEM, 10%FBS, 2 mM/L glu-
tathione, 100 u/ml penicillin/streptomycin. Cells were
serum starved in α-MEM, 0.1%FBS, 2 mM/L glutathione,
100 u/ml penicillin/streptomycin for 24 hours prior to
preparation of total RNA for microarray analysis.
Affymetrix genechip expression analysis
Total RNA was prepared from two independent biological
replicates of the HEK-TERV and HEK-TERST cell lines and
used for whole genome expression analysis as previously
described [5]. Data from Affymetrix CEL files was then
normalized using the robust multiarray average (RMA)
method [6]. Briefly in the original analysis of Affymetrix
data, genes called Absent by the Microarray Suite 5.0 soft-
ware in all hybridizations and genes that were called no
change (NC) in more than one ST-TERV Affymetrix com-
parison file were filtered out leaving 2545 probes for Sig-
nificance Analysis of Microarrays (SAM) analysis [7]. After
data normalization, SAM analysis was performed on the
remaining 2545 probe sets using the following relevant
parameters: ∆ = 0.26, fold-change = 1.5, number permu-
(A) Venn diagram of the number of genes identified as  changed between HEK-TERST and HEK-TERV cells using the  AB and Affymetrix platforms and an equivalent number of  replicates Figure 1
(A) Venn diagram of the number of genes identified as 
changed between HEK-TERST and HEK-TERV cells using the 
AB and Affymetrix platforms and an equivalent number of 
replicates. Approximately 40% of previously identified genes 
were verified with equal replicates and 4.2 times as many 
genes were significant on the AB platform. (B) Venn diagram 
of the number of genes identified including two additional 
technical replicates for each cell line. Approximately 61% of 
previously identified genes were verified with these data, and 
7.6 times as many genes were significant on the AB platform. 
(C) Venn diagram of the 548 re-analyzed Affymetrix genes 
and the 1927 AB genes without technical replicates. (D) 
Venn diagram of the 548 re-analyzed Affymetrix genes and 
the 3478 AB genes with technical replicates.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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tations = 1000, RNG seed = 1234567, median FDR < 3%,
significant probes = 555, predicted false positives = 17. For
the revised Affymetrix analysis presented here, all probe
sets with at least one present call (n = 15229) were
included in the SAM analysis using the following relevant
parameters: ∆ = 0.59, fold-change = 1.5, number permu-
tations = 500, RNG seed = 1234567, median FDR < 3%,
significant probes = 668, predicted false positives = 16.
AB Expression array system analysis
The quality of the RNA from the samples was evaluated
using the Agilent Bioanalyzer 2100 (Agilent Technologies,
Palo Alto, CA). A minimum Bioanalyzer RNA Integrity
Number (RIN) value of 8 was required prior to RNA labe-
ling. One µg of total RNA from each sample was used to
synthesize DIG-labeled cRNA as described by the Applied
Biosystems Chemiluminescent RT-IVT Labeling protocol
(Applied Biosystems, Foster City, CA). A total of 36 µg of
labeled cRNA (18 µg for each process replicate) from each
RT-IVT reaction was hybridized onto two Applied Biosys-
tems Human Genome Survey Microarrays following the
manufacturer's recommendations. Microarrays were ana-
lyzed using the AB1700 Chemiluminescent Microarray
Analyzer. Two technical replicates were produced for each
biological replicate, for a total of eight hybridizations.
For each gene, the expression values were normalized
across arrays by quantile normalization [8]. "Detectable"
calls for gene expression were based on Applied Biosys-
tems recommendations (signal/noise ratio >3.0 and FLAG
values <5000). A gene had to be called "detectable" in 3
out of 4 replicates in at least one tested sample group
(either HEK-TERST or HEK-TERV) to be retained for fur-
ther analysis. From the initial dataset of 33096 probes,
17710 probes passed this filter and were used in subse-
quent SAM analyses. Significance analysis using the SAM
software was performed on the four hybridizations
(excluding technical replicates) using the following rele-
vant parameters: ∆ = 0.77, fold-change = 1.5, number per-
mutations = 500, RNG seed = 1234567, median FDR <
3%, significant probes = 1554, predicted false positives =
51. For analysis of all eight hybridizations including tech-
nical replicates, SAM analysis was performed with the fol-
lowing parameters: ∆ = 0.84, fold-change = 1.5, number
permutations = 500, RNG seed = 1234567, median FDR <
3%, significant probes = 3663, predicted false positives =
100. Expression fold-changes between TERST and TERV
groups were derived from the mean expression level of a
gene in all four replicates. A complete dataset for the AB
microarray data has been deposited in the ArrayExpress
database, accession number E-MEXP-519. The Affymetrix
dataset is available at ArrayExpress, accession number E-
MEXP-156.
Gene network pathway analysis
Gene Ontology (GO) annotations were analyzed using
the GOstat software [9,10] and with the Panther Protein
Classification System [11] to identify functional annota-
tions that were significantly enriched in this gene set com-
pared to the entire human genome. Gene lists altered by
SV40 ST were mapped onto biological pathways that were
significantly represented. Lists of significantly changed
genes were similarly analyzed using Ingenuity Pathway
Analysis [12]. Gene lists were mapped to canonical path-
ways and relationships were extracted from the Ingenuity
Pathways Knowledgebase. Lists were also loaded and ana-
lyzed with GenMAPP [13] and genes altered by SV40 ST
(A) Scatterplot comparison of the log2 ratio of gene expres- sion data between HEK-TERST and HEK-TERV cells Figure 2
(A) Scatterplot comparison of the log2 ratio of gene expres-
sion data between HEK-TERST and HEK-TERV cells. Log2 
ratios from the AB platform are plotted on the y-axis and 
from the Affymetrix platform on the x-axis. The genes plot-
ted include any gene identified as significantly changed on 
either platform. (B) Scatterplot comparison similar to panel 
(A), except that only the 278 genes significantly altered on 
both platforms are shown. (C) Scatterplot of the log2 ratio 
of HEK-TERST and HEK-TERV cells comparing different 
technical replicates on the AB platform. (D) Scatterplot 
comparison as in panel (C), except comparing biological rep-
licates on the AB platform. (E) Scatterplot comparison of the 
log2 transformed absolute signal from HEK-TERST cells from 
two technical replicates on the AB platform. (F) Scatterplot 
comparison of the log2 transformed absolute signal from 
HEK-TERST cells from two biological replicates on the AB 
platform.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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were analyzed for interaction with the Wnt signaling path-
way.
TaqMan assay validation
Validation of microarray results was done using Applied
Biosystems TaqMan Gene Expression Assays [14]. Total
RNA from the original samples was converted to cDNA
using the Applied Biosystems High Capacity cDNA
Archive Kit. Ten ng of cDNA was used per TaqMan reagent
based Reaction. Each TaqMan assay was run on an
Applied Biosystems 7900HT FAST Real-Time PCR system
in quadruplicates and expression fold-changes (normal-
ized to the endogenous control GAPDH) between HEK-
TERST and HEK-TERV were derived using the comparative
CT method [15]. Concordance of fold-change compara-
bility of selected genes between microarray and TaqMan
data was determined by the Pearson correlation coeffi-
cient.
Immunoblots
Immunoblots were performed as previously described [5].
The human activated Notch 2 antibody (Abcam Inc.,
Cambridge, MA, cat# Ab8926) was derived using a syn-
thetic peptide CRDASNHKRREPVGQD, corresponding to
amino acids 1719–1733 of Human activated Notch2 and
used at 1:500.
Promoter analysis
Promoter Analysis was performed using our automated
CONFAC software, which identifies promoters sequences
within 3 kb upstream of transcription start sites and the
first intron of each gene that are conserved between
human and mouse genomes [16]. The position weight
matrices are those from the MATCH software using the
TRANSFAC Professional 8.3 database.
Drug sensitivity assays
HEKTER-LUK and HEKTER-ST cells were treated with
appropriate concentrations of vehicle (Ethanol or
DMSO), 2.4µM cyclopamine (C-8700, LC laboratories,
Woburn, MA, USA), or 1 nM γ-secretase inhibitor (S-
1120, A.G. Scientific, Inc. San Diego, CA, USA). Cells were
initially incubated with the compounds for 48 hours and
the incubation was extended for another 24 hours with
fresh media containing vehicle or drug. Cells were plated
at 2 × 104/well in a 96-well plate and viability was deter-
mined by the MTT assay. Twenty µl of 3 mg/mL 3- [4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) was added to each well and incubated for 4 hours
at 37°C. Elution of the precipitate was performed with
100 µL of DMSO and 10µL of Tris-Glycine buffer. Cell via-
bility was calculated from the absorption values obtained
at 570 nm using an automated enzyme-linked immuno-
sorbent assay (ELISA) reader. In a separate set of experi-
ments, both HEK-TERV and HEK-TERST cells were plated
at 1 × 105/well in a 6 well plate containing α-MEM media
(Cellgro Mediatec Inc, Herndon, VA, USA) supplemented
with 10% FBS and allowed to attach overnight. Media was
then replaced with fresh medium containing either vehi-
cle or drug. Cell viability was determined after 72 hrs by
Trypan blue exclusion. Fifty µl of cell suspension was
mixed with 50 µl of Trypan blue isotonic solution (0.2%;
w/v), and cell viability was determined on a hemocytom-
eter by phase contrast microscopy.
(A) QRTPCR validation of the AB Expression Array System  measured Fold Change of gene expression data between  HEK-TERST and HEK-TERV cells Figure 3
(A) QRTPCR validation of the AB Expression Array System 
measured Fold Change of gene expression data between 
HEK-TERST and HEK-TERV cells. Fold change values from 
the AB platform are plotted on the x-axis and TaqMan assay 
based QRTPCR fold change is plotted on the y-axis. Data for 
the same set of genes are shown in all panels (A-F). (B) 
QRTPCR validation of the Affymetrix measured Fold Change 
of gene expression data between HEK-TERST and HEK-
TERV cells. Fold change values from the Affymetrix platform 
are plotted on the x-axis and TaqMan assay based QRTPCR 
fold change is plotted on the y-axis. (C) Comparison of 
SYBR Green reagent based QRTPCR data to the AB Expres-
sion Array System fold change data. (D) Comparison of 
SYBR Green regent based QRTPCR data to the Affymetrix 
fold change data. (E) Comparison of the SYBR Green regent 
based QRTPCR data and the TaqMan assay based QRTPCR 
data. (F) Scatterplot comparison of the Affymetrix measured 
and AB Expression Array System measured Fold Change of 
gene expression data between HEK-TERST and HEK-TERV 
cells.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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Results
Cross-platform microarray analysis
We assessed the cross-platform comparability and per-
formance of the Affymetrix U133AB GeneChip with the
AB 1700 Chemiluminescent Microarray Analyzer using
RNA prepared from HEK-TERV cells that do not express
SV40 ST and HEK-TERST cells that do express SV40 ST.
Two biological replicates were analyzed on each array
platform, and in addition, two technical replicates were
performed on the AB platform. To make a fair comparison
of the sensitivity of the two systems, we analyzed the AB
data without the technical replicates so that equal num-
bers of hybridizations were used for analysis of each tech-
nology. Significantly changed genes were identified using
identical parameters of 1.5 fold change and a false discov-
ery rate of 3% using SAM analysis [7]. Figure 1A shows a
Venn diagram of the number of genes altered by expres-
sion of SV40 ST that were detected by each platform alone
or by both platforms. Figure 1B shows a Venn diagram of
the number of genes in common and detected when an
additional set of AB technical replicates are included in
the analysis. Previously, we identified 456 genes whose
expression was significantly increased/decreased due to ST
expression on the Affymetrix platform [5]. The AB plat-
form identified 2014 significantly different probe sets cor-
responding to 1927 unique genes using identical
replicates and analysis techniques. The total number of
genes identified by both platforms was 185 or 41% of the
456 genes initially identified with the U133 GeneChips.
When technical replicates were included in the AB analy-
sis, 3478 unique genes were identified as affected by SV40
ST [see Additional file 1], increasing the number of con-
firmed genes from our previous analysis to 278 genes
(61%) from the original set of 456 genes. Of those 456
genes, ten corresponded to EST sequences that had no
equivalent probes on the AB microarrays, so at most 446
genes could have been confirmed.
Because our original SAM analysis of our Affymetrix data
was performed on a prefiltered set of only 2545 probe
sets, we performed another SAM analysis on a larger set of
Affymetrix probes. For the revised SAM analysis, we
included all of the 15,229 Affymetrix probe sets with a
present call in at least one sample. Despite the larger
number of probe sets included in the analysis, the number
of significant genes identified increased by only 92 genes
for a total of 548 significant genes [see Additional file 2].
Of those 548 genes, 202 (37%) overlapped with the 1927
AB genes identified without technical replicates (Figure
1C). When compared to the 3478 genes identified on the
AB platform with technical replicates, there were 306
genes (56%) that overlapped (Figure 1D). These data
show that the AB platform was able to measure significant
changes in many more genes than the Affymetrix platform
and that additional technical replicates nearly doubled
the number of detectable differences. A total of 178 genes
called significant by the Affymetrix platform were not con-
firmed using the AB1700 [see Additional file 3].
To directly compare the expression data from the two
microarray platforms, scatter plots of the log2 change
between the TERST and TERV cell lines were generated for
two datasets. The first dataset included any of the 3666
genes that were identified as significant on either platform
(Figure 2A), while the second dataset included only the
278 genes that were significantly changed on both plat-
forms (Figure 2B). As can be seen, the correlation for the
genes found by both platforms is quite high (R2 > 0.77),
and consequently the confidence for the differential
expression of these genes is also very strong. A complete
list of these 278 genes is included in the Supplementary
Data [see Additional file 4], and it includes many genes
that we characterized previously such as myc, CD24,
PAR2/F2R, PAR3/F2RL1, PAR4/F2RL2, IL-8, IQGAP2,
ICAM1, and HOXB6. For comparison, the reproducibility
of biological (R2 > 0.71) and technical (R2 > 0.74) repli-
cates on the AB platform is also shown for the 3478 genes
with significant changes (Figures 2C and 2D). Also shown
are the scatterplots for absolute signal in technical and
biological replicates (R2 > 0.97) for the HEK-TERST cell
line using the AB platform (Figures 2E and 2F). These data
show that the AB platform data are highly reproducible.
The difference in the range of the data from the two
expression platforms in Figures 2A and 2B is worth not-
ing. In general, the dynamic range of the Affymetrix data
was smaller (from 2-5 to 23) than the AB dynamic range
(from 2-9 to 25). This may account for the greater number
of genes that were significantly altered on the AB platform
due to the nature of chemiluminescence with higher sig-
nal range and lower background. In addition, the poten-
tial for greater sensitivity of 60-mer oligonucleotides
compared to 25-mer oligonucleotides, as well as the
sequence specificity of the 60-mers may also account for
the greater number of genes that were significantly altered
on the AB platform.
QRTPCR taqman validation
As an independent method to determine the accuracy of
expression changes on the two platforms, we chose to per-
form TaqMan assay based QRTPCR on 49 genes that we
previously determined were altered by SV40 ST using
Affymetrix arrays. Figure 3A shows the correlation of the
QRTPCR TaqMan assay based data and the AB microarray
data was excellent (R2 > 0.71). In contrast, the correlation
of the Affymetrix data with the same TaqMan assay data
was fairly low (R2 ~0.47, Figure 3B). Moreover, only 22 of
the 49 genes (45%) were confirmed by TaqMan assay
based QRTPCR. These data contrast sharply with our ear-
lier data in which 43 of 46 genes (93%) were confirmedBMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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using SYBR Green reagent based QRTPCR to quantitate
mRNA changes [5]. To resolve this conflict, we plotted our
earlier SYBR Green reagent based QRTPCR against the AB
microarray data (Figure 3C) and the Affymetrix data (Fig-
ure 3D). The large difference in the scales of the TaqMan
data and the SYBR Green reagent data indicate that the
SYBR Green regent based QRTPCR overestimates changes
in gene expression. Nevertheless, the SYBR Green and
TaqMan assay based QRTPCR data were very well corre-
lated (Figure 3E), demonstrating that the discrepancy is
largely a matter of sensitivity and signal amplification.
Interestingly, the Affymetrix data was better correlated
with the AB microarray data than it was with either of the
QRTPCR data sets (Figure 3F). This may be due to the fun-
damental differences between microarray hybridization
data and quantitative real-time PCR.
To validate the 3200 genes that were uniquely identified
with the AB technology, we selected an additional 23
genes for TaqMan assay based QRTPCR validation (Table
1). The validation data for these genes was equally well
correlated with the AB microarray data (R2 > 0.71). A com-
plete list of the 3478 genes identified with the AB platform
is given in the Supplementary Data [see Additional file 1].
Pathway annotation of ST-regulated genes
We analyzed the Gene Ontology (GO) annotation of the
3478 genes identified with the AB Microarray using the
GOstat software [9] and identified functional annotations
that were significantly enriched in this gene set compared
to the entire human genome. The significant GO catego-
ries are summarized in Table 2 and parallel those catego-
ries we previously observed [5]. We also analyzed the
same gene set with the Panther Protein Classification Sys-
tem [11] and obtained similar results shown in Table 3.
SV40 ST may increase notch signaling
Among the genes we observed to be upregulated by SV40
ST were Delta-like ligand 1 (DLL1, up 5.3 fold), a human
homolog of the D. melanogaster ligand delta, and Jagged 1
(JAG1, up 1.6 fold) a homolog of the Notch ligand serrate.
To determine whether the Notch receptor was expressed
in HEK-TERST cells, we examined the expression profiling
data from both our Affymetrix and AB expression studies.
Data from both platforms indicated that while the Notch
1, Notch 3, and Notch 4 homologs had very low expres-
sion levels, the Notch 2 receptor was highly expressed in
both the HEK-TERV and the HEK-TERST cell lines. More-
over, both platforms indicated that there was little if any
change in Notch 2 expression between the HEK-TERV and
HEK-TERST cells.
In a recent study [17], mesothelial cells required both
SV40 ST and SV40 LT for induction of Notch receptor
expression, and required activation of the MAPK-ERK
pathway. Since the HEK-TERV cells express both SV40 LT
and mutant H-Ras-V12, they have constitutive activation
of the MAPK-ERK pathway even in the absence of SV40
Table 1: TaqMan assay based QRTPCR and Microarray Fold changes for 23 genes. Genes that were not significant on the Affymetrix 
column are indicated (n.s.). Twenty genes were validated and three showed little change (BIRC5, WNT7A, and ETS1).
Gene Expression Array SystemFold Change TaqMan Fold Change Affymetrix Fold Change
DLL1 5.3 16.3 n.s.
SERPINB3 4.8 10.2 n.s.
NTRK2 6.9 6.5 3.21
STC2 6.9 5.7 n.s.
DKK1 5.1 5.1 1.54
CLDN2 4.8 3.8 n.s.
AK5 3.2 3.8 3.98
GLI2 2.2 2.5 n.s.
MID1 2.1 2.0 n.s.
WNT5B 2.0 1.9 n.s.
GADD45B 2.2 1.8 n.s.
HOXB6 1.6 1.7 2.11
BIRC5 1.5 1.1 n.s.
WNT7A 1.7 1.1 n.s.
ETS1 2.5 1.1 1.54
GFI1 -6.7 -8.6 n.s.
CXCL3 -6.8 -9.2 n.s.
CLDN4 -6.9 -11.9 n.s.
NCAM1 -6.7 17.4 n.s.
WT1 -7.5 -19.3 n.s.
CXCL5 12.2 -32.6 n.s.
GATA3 -8.8 -126.2 n.s.
NOX5|SPESP1 -10.1 -2193.6 n.s.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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ST. Thus, our data are consistent with the observation that
LT and ERK activation are sufficient to activate Notch
expression. However, the mesothelial cells also constitu-
tively expressed DLL1 and JAG1 ligands with or without
expression of SV40 ST. Thus, in HEK cells, it appears that
ST increases DLL1 and JAG1 expression, which are already
expressed in mesothelial cells. In light of these data, we
predict that enhanced expression of both DLL1 and
Notch2 on the HEK-TERST cells would increase activation
of Notch signaling via cell-cell interactions between adja-
cent HEK-TERST cells.
We next examined the promoters of the genes altered by
ST to determine if they were consistent with activated
Notch signaling. Using our CONFAC software [16], we
compared the promoters of 256 RefSeq genes upregulated
by ST (> 2-fold increase and FDR < 1%) with sets of ran-
dom promoters. Since Notch signals are mediated
through Hairy-enhancer of split 1 (HES1) [18], we pre-
dicted that if Notch signaling played an important role in
regulation of the genes affected by ST, the promoters of
these genes should be enriched for HES1 sites. Our CON-
FAC analysis of these 256 upregulated RefSeq genes found
that 106 genes contained conserved transcription factor
binding sites (TFBS) and that HES1 sites were the single
most significantly enriched TFBS (p = 0.003) in the pro-
moters of these 106 genes (Figure 4A). Of these 106 genes,
91 contained conserved HES1 sites. The ST-upregulated
genes containing multiple conserved HES1 sites included
DLL1, the c-myc oncogene, inhibitor of DNA binding 2
(ID2), frizzled-related protein (FRZB), Dickkopf homolog
1 (DKK1), and hedgehog-interacting protein (HIP). A
complete list of these 106 genes and the number of con-
served HES1 sites in their proximal promoters is given in
the Supplementary Data [see Additional file 5] and the
HES1 site used for this analysis is shown in Figure 4B.
To directly test whether Notch-2 is activated in HEK-
TERST cells, we probed immunoblots of whole cell lysates
from HEK-TERV and HEK-TERST cells using polyclonal
antibodies specific to activated human Notch-2 (Figure
4C). Notch is translated as a ~300 kD full length prepro-
tein (Notch-FL) that is proteolytically cleaved to produce
a mature ~100 kD transmembrane/cytosolic C-terminal
fragment (Notch-TM) and an extracellular N-terminal
fragment [19]. Upon binding of the extracellular fragment
to the DLL1 ligand, the Notch-TM is cleaved by gamma-
secretase [20,21] to produce the intracellular fragment
(Notch-IC) that translocates to the nucleus to activate
transcription [22]. Short exposures of Activated Notch-2
immunoblots indicate no change in activation of Notch-2
between HEK-TERV and HEK-TERST cells, but longer
exposures demonstrated a shorter isoform of Notch-2
present in HEK-TERST cells that is not present in HEK-
TERV cells (Figure 4C). Thus, while there may be
increased Notch signaling in cells expressing SV40 ST, it is
clear that Notch-2 is also activated in the HEK-TERV cells
that do not express SV40 ST.
Table 2: GOStat analysis of Biological Processes that are significantly enriched in the set of 3478 genes found with the AB platform. Of 
those genes only 2476 had recognizable HUGO symbols and 1811 were annotated in the GO database. Shown here is a subset of 20 
representative significant GO annotations. The complete set of 135 significant GO categories together with the identities of the genes 
in each category is included in the supplementary data.
GO Number GO Category Observed Genes Total Genes p-value
GO:0007155 cell adhesion 129 859 2.96E-18
GO:0009611 response to wounding 70 429 9.63E-12
GO:0008283 cell proliferation 78 526 2.69E-10
GO:0006954 inflammatory response 43 225 2.80E-10
GO:0009613 response to pathogen 79 542 3.94E-10
GO:0007154 cell communication 447 4919 1.89E-09
GO:0006950 response to stress 137 1164 3.90E-09
GO:0009653 morphogenesis 145 1307 1.12E-07
GO:0006928 cell motility 35 211 4.47E-06
GO:0006935 chemotaxis 24 124 7.56E-06
GO:0009887 organogenesis 112 1026 1.40E-05
GO:0005578 extracellular matrix 58 453 4.10E-05
GO:0000074 regulation of cell cycle 60 483 8.49E-05
GO:0007243 protein kinase cascade 38 283 0.001
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB cascade 17 91 0.001
GO:0008219 cell death 65 595 0.004
GO:0005911 intercellular junction 19 116 0.004
GO:0000165 MAPKKK cascade 16 92 0.005
GO:0001525 angiogenesis 11 53 0.02
GO:0007219 Notch signaling pathway 5 15 0.05BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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SV40 ST also activates components of the Wnt and 
Hedgehog pathways
Among the genes upregulated by ST were several compo-
nents of the Wnt and Hedgehog pathways (Figure 5),
including the WNT5B ligand (up 2 fold). We also detected
increased levels of the Smoothened receptor (1.9 fold)
and the GLI2 transcription factor (2.2 fold), both media-
tors of Hedgehog signaling, as well as the hedgehog antag-
onist HIP (3.9 fold). Smoothened expression is essential
for Hedgehog signaling [23], and three Hedgehog target
genes, GLI2 [24], HIP [25], and Wnt5A [26], were upreg-
ulated, suggesting that Hedgehog pathways are activated
by SV40 ST and that they contribute to activation of Wnt
signaling. SV40 ST also increased expression of the Wnt
antagonist DKK1 (up 5 fold) that was recently shown to
be a direct target of the Wnt-β-catenin/TCF pathway [27].
While DKK1 was not identified in our original analysis of
the Affymetrix data, it was one of the new 92 genes that
were significantly changed in the revised analysis of the
Affymetrix data. In addition, the Wilm's Tumor suppres-
sor (WT1) gene, which when lost in Wilm's tumors can
result in activation of β-catenin [28], was downregulated
8-fold in HEK-TERST cells. Another member of the Wnt
pathway, transducin-like enhancer of split 4 (TLE4),
which is a homolog of the groucho repressor of the Wnt
pathway and a target of Notch signaling, was increased 1.7
fold by SV40 ST. Three Wnt ligands (WNT5B, WNT11, and
WNT7A), one Wnt receptor (FZD7), and at least fourteen
known Wnt downstream targets [29], including c-myc,
DKK1, and DLL1 were all affected by SV40 ST expression
(Figure 5). Thus, the altered levels of multiple Wnt path-
way components and Wnt target genes strongly suggest
that SV40 ST activates Wnt signaling.
Hedgehog inhibitors, but not Notch inhibitors, kill cells 
expressing SV40 ST
To directly test the importance of the activation of the
Notch and Hedgehog pathways for survival of cells
expressing SV40 ST, we treated HEK-TERV and HEK-
TERST cells with inhibitors of the Notch-activating pro-
tease, gamma-secretase, and the Hedgehog-activated
receptor, Smoothened. While the gamma-secretase inhib-
itor had little effect on survival of HEK-TERV or HEK-
TERST cells, the Smoothened-inhibitor, cyclopamine, had
Table 3: Significantly overrepresented GO categories from the Panther annotation database using the same gene set as Table 1.
Biological Process Observed Genes Expected Genes p-value
Cell structure and motility 175 118 3.6E-07
Cell communication 207 150 3.4E-06
Protein glycosylation 41 19 4.1E-06
Signal transduction 512 424 4.5E-06
Cell adhesion 107 68 5.6E-06
Carbohydrate metabolism 96 60 9.6E-06
Immunity and defense 220 166 2.5E-05
Protein modification 164 120 6.4E-05
Cell proliferation and differentiation 127 89 8.1E-05
Cell cycle 141 101 8.3E-05
Oncogenesis 101 69 1.6E-04
Cell structure 106 73 1.6E-04
Protein metabolism and modification 381 319 1.9E-04
Cell cycle control 75 49 2.3E-04
Developmental processes 304 249 2.4E-04
Extracellular matrix protein-mediated signaling 17 6 2.7E-04
Intracellular signaling cascade 138 103 4.1E-04
Tumor suppressor 26 13 0.001
Other polysaccharide metabolism 27 14 0.001
Apoptosis 81 57 0.001
Other metabolism 90 65 0.002
Receptor protein tyrosine kinase signaling pathway 36 21 0.002
Skeletal development 26 14 0.002
NF-kappaB cascade 18 8 0.003
Cell motility 52 35 0.003
Nucleoside, nucleotide and nucleic acid metabolism 441 390 0.004
Cell adhesion-mediated signaling 52 35 0.004
Mesoderm development 83 62 0.005
DNA replication 20 11 0.007
DNA metabolism 53 37 0.007
Lipid, fatty acid and steroid metabolism 105 82 0.008
Stress response 35 22 0.008BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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a marked killing effect on HEK-TERST cells (Figure 6).
Moreover, the SV40 ST expressing cells were significantly
more sensitive to cyclopamine's killing effects, suggesting
that SV40 ST sensitizes cells by making them dependent
on pro-survival signals from the hedgehog pathway.
Discussion
We have used a relatively new commercial DNA microar-
ray platform to analyze the genes that are affected by
expression of SV40 ST in HEK cells and to compare the
performance of two single-color, oligonucleotide-based
technologies. In general, the AB microarray platform out-
performed the Affymetrix platform in both sensitivity and
accuracy. The AB platform identified over 3.5 times as
many genes (1927 vs. 548) using equivalent replicates
and analyses, and over six times as many genes (3478 vs.
548) with additional technical replicates. The AB data was
highly reproducible, had a greater dynamic range than the
Affymetrix data, and correlated much better with TaqMan
assay based QRTPCR validation data in our experiments.
The fact that the AB microarray uses 60-mer oligonucle-
otides compared to the 25-mer probe sets used in Affyme-
trix microarrays likely contributed greatly to the
differences in specificity, sensitivity, and accuracy. Apart
from the difference in the length of the oligonucleotides,
the actual sequences that were queried were different
between the two platforms, making cross-platform anno-
tation somewhat difficult. The TaqMan assay based QRT-
PCR assays used were not designed biased to any
particular region of each target transcript, while the
probes on the AB microarray were biased to the 3' UTR
(within 1500 bp of the 3' UTR), making these assays inde-
pendent for mRNA quantitation. However, each probe on
the AB microarray queries sequences in common to all
verified alternative splice forms of each gene, while the
TaqMan assays can measure a subset of specific splice
forms. Thus, in the few instances in which the TaqMan
and AB microarray data did not agree, it is likely to be
either a function of higher sensitivity of TaqMan or that
the TaqMan assays are targeting a subset of spliced tran-
scripts that the microarrays measures. Moreover, it is
entirely possible that the Affymetrix and AB platforms can
be measuring alternative splice forms of the same gene.
The classes of genes that were altered based on GO ontol-
ogies were in general the same as that observed previously
in our original analysis [5]. Specifically, we once again
observed large decreases in expression of immune
response genes, and changes in genes involved in cell
cycle regulation, oncogenesis, cellular adhesion, and sig-
nal transduction. However, the statistical significance of
these observations was increased due to the greater
number of genes detected. For example, we found 70
genes annotated for wounding response were affected (p
= 9.63E-12), while our earlier study found 48 genes (p =
3.46E-4). In addition, a number of new, biologically sig-
nificant observations became apparent from the AB
expression data that we did not observe previously.
Our initial analysis with Affymetrix arrays identified
downregulation of interleukin 8 (IL-8) and interleukin 1β
(IL-1β). With the AB platform, we also observed downreg-
ulation of interleukin 1α (IL-1α), interleukin 1 receptor
(IL1R), interleukin 6 (IL-6) as well as the chemokine lig-
ands CXCL2, CXCL3, CXCL5, CCL20, and tumor necrosis
(A) Plot of the average frequency of HES1 sites in genes  upregulated by ST > 2-fold and in a random control list of  200 genes Figure 4
(A) Plot of the average frequency of HES1 sites in genes 
upregulated by ST > 2-fold and in a random control list of 
200 genes. (B) Sequence logo of the position weight matrix 
for HES1 sites based on the TRANSFAC database.(C) Immu-
noblot of whole cell lysates prepared from HEK-TERST and 
HEK-TERV cells and probed with antibodies specific for the 
activated human Notch-2. Activated Notch-2 is equally 
present in both cell lines (right), although longer exposures 
(left) reveal a shorter isoform that is more abundant in cells 
expressing SV40 ST.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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Impact of SV40 ST on the Notch, Wnt, and Hedgehog Pathways Figure 5
Impact of SV40 ST on the Notch, Wnt, and Hedgehog Pathways. Schematics of the Notch, Wnt, and Hedgehog pathways are 
shown. Genes with significantly increased mRNA's in HEK-TERST cells compared to HEK-TERV cells are shown in red, while 
genes significantly decreased are shown in green. Sets of downstream targets of the Wnt pathway are grouped in boxes, as are 
sets of c-myc downstream targets. Activation of the Hedgehog pathway due to increased HIP, SMO, and GLI2 levels results in 
increased Wnt ligand expression. Activation of Wnt signaling increases c-myc, activating and repressing multiple downstream 
target genes. Wnt pathway activation also feeds back to activate expression of Notch ligands such as DLL1.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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factor (TNF). In addition, several components of the TNF-
NFκB signal transduction cascade were downregulated,
including the TNF receptor associated 5 (TRAF5) protein,
toll-like receptor 2 (TLR2), receptor-interacting protein
kinase 2 (RIPK2), interleukin-1 receptor-associated kinase
2 (IRAK2), NFKB1, REL, Caspase 8 (CASP8), and TNF-
related apoptosis inducing ligand (TRAIL/TNFSF10). The
strong downregulation of multiple components along the
TNF-NFκB pathway explains why so many inflammatory
genes are downregulated by SV40 ST. Furthermore, we
observed changes in components of every known death
receptor pathway (Figure 7), including FAS, TNF, CASP8,
TRAIL, TL1 [30], and apoptosis signal-regulating kinase 1
(ASK1) [31], thus providing mechanisms for SV40 ST
induced resistance to apoptosis.
In our earlier study [5], we also determined that cell-cell
adhesion and integrin signaling were altered in cells that
express SV40 ST. The larger dataset of altered genes from
the AB platform provides additional insights into these
changes. In addition to our earlier observations on
ICAM1, VCAM1, junction plakoglobin (JUP), proto-cad-
herins, collagens, and laminins, the AB expression data
showed decreases in integrins α2, α3, αV, αX, and β8 and
increases in integrins α4 and α7. Integrins α3, α4 and α7
mediate binding to laminins, while α2 integrin binds to
collagen, and integrin αVβ8 is an RGD receptor (reviewed
in [32]). We also observed alterations in both directions
for seven laminin genes and seven collagen genes, suggest-
ing that, in addition to modulating cellular adhesion in
favor of laminin-binding receptors, SV40 ST is altering the
composition of the extracellular matrix. The AB data also
provided additional evidence for decreased cell-cell adhe-
sion through downregulation of neural cell adhesion
molecule 1 (NCAM1), L1 cell adhesion molecule
(L1CAM), claudin 1 (CLDN1), and junction adhesion
molecule 2 (JAM2).
Regarding cellular proliferation, we had previously
reported increased levels of myc and src activation. The
additional expression data described here show increased
levels of epidermal growth factor receptor (EGFR) and
insulin-like growth factor 2 (IGF2), providing potential
mechanisms by which growth-factor signaling cascades
can be stimulated by SV40 ST. Moreover, we observed
activation of the Wnt signaling pathway, providing
another mechanism that may explain the observed
increases in myc expression, since myc is a known down-
stream target of β-catenin [33] and Wnt signaling provides
resistance to myc-induced apoptosis [34]. We also
observed increased expression of the Wnt5b ligand, as
well as DKK1, a recently validated downstream target of
Wnt signaling [27]. At least fourteen known Wnt down-
stream targets [29] were affected by SV40 ST, further sup-
porting the evidence that Wnt signaling is activated by
SV40 ST.
The observation that cyclopamine killed 50–60% of HEK-
TERST cells, but had little effect on HEK-TERV cells sug-
gests that SV40 ST exerts changes within the cell that
makes it dependent on hedgehog signals for survival.
However, the lack of an effect of gamma-secretase inhibi-
tors suggests that Notch signaling is not essential for sur-
vival in cells expressing SV40 ST.
Conclusion
Our data show that the AB platform had substantially
higher sensitivity than the Affymetrix platform in these
Antitumor activities of cyclopamine and γ-secretase inhibitor  against HEKTER-LUK and HEKTER-ST cell lines Figure 6
Antitumor activities of cyclopamine and γ-secretase inhibitor 
against HEKTER-LUK and HEKTER-ST cell lines. (A) Survival 
of HEK-TERV and HEK-TERST cells determined by MTT 
assay after treatment with vehicle, 2.4µM Cyclopamine or 1 
nM γ-secretase inhibitor for 72 hrs. Mean and standard error 
are shown for each treatment. Percent cell survival was com-
puted relative to untreated cells. (B) Survival of HEK-TERST 
cells determined by Trypan Blue exclusion assay after treat-
ment of 1 × 105 cells with vehicle, 2.4µM Cyclopamine or 1 
nM γ-secretase inhibitor for 72 hrs.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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experiments, detecting four times as many gene changes.
Moreover, the AB data was highly correlated with QRT-
PCR validation data (R2 = 0.71) while Affymetrix data had
lower correlation with QRTPCR results (R2 = 0.47).
Among the Wnt target genes that were upregulated by
SV40 ST, we observed changes in key developmental reg-
ulators, including the DLL1 and JAG1 ligands for Notch.
However, activated Notch-2 was detected in both cell
lines, suggesting that its activation, while possibly
increased by SV40 ST, was not dependent on SV40 ST.
Finally, the increased levels of the Smoothened receptor
(SMO) and three Hedgehog target genes (GLI2, HIP, and
Wnt5A), suggest that Hedgehog pathways are also acti-
vated by SV40 ST, and the cell death induced by
cyclopamine shows that Hedgehog activation is critical to
survival for cells expressing SV40 ST. These data support a
model in which Hedgehog signaling activates Wnt signal-
ing, which in turn activates Notch signaling (Figure 5).
The activation of all three of these developmental path-
ways provides a mechanism for our earlier conclusions [5]
that SV40 ST induces a de-differentiated phenotype in
transformed human cells. Together, the changes in adhe-
sion, proliferation, apoptosis, and differentiation orches-
trated by SV40 ST provide several insights into the
pathways that are disrupted upon transformation of
human cells.
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Effect of SV40 ST on Death Receptor Pathways Figure 7
Effect of SV40 ST on Death Receptor Pathways. The diagram is colored as in Figure 5. SV40 ST downregulates pro-apoptotic 
components of all death receptor pathways and upregulates anti-apoptotic components such as survivin.BMC Cancer 2006, 6:54 http://www.biomedcentral.com/1471-2407/6/54
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